Cargando…
The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Fur...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884200/ https://www.ncbi.nlm.nih.gov/pubmed/29755284 http://dx.doi.org/10.1155/2018/1901896 |
_version_ | 1783311778746204160 |
---|---|
author | Ryan, Sean Visgauss, Julia Kerr, David Helmkamp, Joshua Said, Nicholas Vinson, Emily O'Donnell, Patrick Li, Xuechan Jung, Sin-Ho Cardona, Diana Eward, William Brigman, Brian |
author_facet | Ryan, Sean Visgauss, Julia Kerr, David Helmkamp, Joshua Said, Nicholas Vinson, Emily O'Donnell, Patrick Li, Xuechan Jung, Sin-Ho Cardona, Diana Eward, William Brigman, Brian |
author_sort | Ryan, Sean |
collection | PubMed |
description | INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. METHODS: We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis. Four expert readers interpreted each patient's MRI independently and provided a diagnosis. Additionally, a formula based on imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2 pathologic diagnoses. RESULTS: The accuracy of MRI readers was 73.5% (95% CI 61–86%) with substantial interobserver agreement (κ=0.7022). The formula had an accuracy of 71%, which was not significantly different from the readers (p=0.71). The formula and expert observers had similar sensitivity (83% versus 83%) and specificity (64.5% versus 67.7%; p=0.659) for detecting WDLs. CONCLUSION: The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between lipoma and WDLs. |
format | Online Article Text |
id | pubmed-5884200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58842002018-05-13 The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing Ryan, Sean Visgauss, Julia Kerr, David Helmkamp, Joshua Said, Nicholas Vinson, Emily O'Donnell, Patrick Li, Xuechan Jung, Sin-Ho Cardona, Diana Eward, William Brigman, Brian Sarcoma Research Article INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. METHODS: We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis. Four expert readers interpreted each patient's MRI independently and provided a diagnosis. Additionally, a formula based on imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2 pathologic diagnoses. RESULTS: The accuracy of MRI readers was 73.5% (95% CI 61–86%) with substantial interobserver agreement (κ=0.7022). The formula had an accuracy of 71%, which was not significantly different from the readers (p=0.71). The formula and expert observers had similar sensitivity (83% versus 83%) and specificity (64.5% versus 67.7%; p=0.659) for detecting WDLs. CONCLUSION: The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between lipoma and WDLs. Hindawi 2018-03-19 /pmc/articles/PMC5884200/ /pubmed/29755284 http://dx.doi.org/10.1155/2018/1901896 Text en Copyright © 2018 Sean Ryan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ryan, Sean Visgauss, Julia Kerr, David Helmkamp, Joshua Said, Nicholas Vinson, Emily O'Donnell, Patrick Li, Xuechan Jung, Sin-Ho Cardona, Diana Eward, William Brigman, Brian The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title | The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title_full | The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title_fullStr | The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title_full_unstemmed | The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title_short | The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing |
title_sort | value of mri in distinguishing subtypes of lipomatous extremity tumors needs reassessment in the era of mdm2 and cdk4 testing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884200/ https://www.ncbi.nlm.nih.gov/pubmed/29755284 http://dx.doi.org/10.1155/2018/1901896 |
work_keys_str_mv | AT ryansean thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT visgaussjulia thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT kerrdavid thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT helmkampjoshua thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT saidnicholas thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT vinsonemily thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT odonnellpatrick thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT lixuechan thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT jungsinho thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT cardonadiana thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT ewardwilliam thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT brigmanbrian thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT ryansean valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT visgaussjulia valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT kerrdavid valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT helmkampjoshua valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT saidnicholas valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT vinsonemily valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT odonnellpatrick valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT lixuechan valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT jungsinho valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT cardonadiana valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT ewardwilliam valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing AT brigmanbrian valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing |